| Literature DB >> 34296454 |
Tiffany Mak1, Andrew W Jones1,2, Paul Nurse1,3.
Abstract
Cell growth is orchestrated by a number of interlinking cellular processes. Components of the TOR pathway have been proposed as potential regulators of cell growth, but little is known about their immediate effects on protein synthesis in response to TOR-dependent growth inhibition. Here, we present a resource providing an in-depth characterisation of Schizosaccharomyces pombe phosphoproteome in relation to changes observed in global cellular protein synthesis upon TOR inhibition. We find that after TOR inhibition, the rate of protein synthesis is rapidly reduced and that notable phosphorylation changes are observed in proteins involved in a range of cellular processes. We show that this reduction in protein synthesis rates upon TOR inhibition is not dependent on S6K activity, but is partially dependent on the S. pombe homologue of eIF4G, Tif471. Our study demonstrates the impact of TOR-dependent phospho-regulation on the rate of protein synthesis and establishes a foundational resource for further investigation of additional TOR-regulated targets both in fission yeast and other eukaryotes.Entities:
Keywords: TOR regulation; phosphoproteomics; protein synthesis
Mesh:
Substances:
Year: 2021 PMID: 34296454 PMCID: PMC8365262 DOI: 10.15252/embj.2021107911
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 14.012
Figure 1TOR activity is a major regulator of cellular protein synthesis rates
Measuring active protein synthesis using the methionine analogue, L‐homopropargylglycine (HPG) and measuring the change in rates of mass doubling and protein synthesis upon inhibition of TOR activity.
Density plot showing the measured fluorescence intensity distribution of individual cells for each time point after HPG addition. Time is represented on the y‐axis, with the bottom of the distribution plot aligning to the corresponding time point.
Median fluorescence intensity of the distribution plots in A plotted against the indicated time after HPG addition. Linear regression line fitted from 5 min onwards.
Growth rates as measured by the change in optical density (OD595) over time for wild type (C) and Torin1‐resistant (D) cells upon 5 µM of Torin1 treatment (at T = 0 min). Respective strains were treated with the DMSO vehicle alone to control for potential effects of the solvent on cell growth. Logarithmic values of the OD595 increase are plotted against time in minutes. Data aggregated from three independent experiments with error bars representing the standard deviations (SD). Linear regressions were fitted using the curve‐fitting function on Prism9. Ratios in the rate of mass doubling (as calculated from gradient of regression lines detailed in Materials and Methods) of Torin1‐treated cells to DMSO control were 0.34 in wild type (C) and 0.97 for Torin1‐resistant (D) cells.
Rate of protein synthesis as measured by the amount of HPG incorporation after 20 min of differing time intervals (0–60 min) of 5 µM Torin1 for wild type (green) and tor1∆ (yellow). Values are normalised to T = 0 min. Exponential one‐phase decay non‐linear regressions were fitted using the curve‐fitting function on Prism9. Data aggregated from 3 independent experiments with error bars representing the standard deviations (SD).
Growth rates for wild type and tor1∆, as measured by the change in optical density (OD595) over time. Linear regressions fitted with Prism9.
Figure 2TOR‐dependent phosphoproteomic changes identifies conserved proteins with potential roles in modulating rates of protein synthesis
Investigating the protein expression levels for the phosphoproteomics time course study and validation of experimental conditions based on known indirect TOR phosphorylation targets.
Scatter plot showing the protein levels in wild type cells after 40 min of Torin1 (5 µM) addition plotted against the corresponding values for the same protein in Torin1‐resistant cells after 40 min. Dark grey dashed lines at x = ±1 indicate the 2‐fold threshold, of which no proteins exceeded in the study. The light grey dashed line represents y = x, plotted as guide to indicate positive correlation in protein levels between wild type and Torin1‐resistant cells.
Frequency distribution of the proteins levels after 40 min of Torin1 treatment in wild type cells (n = 3,380), with 98% of all proteins (3,314/3,380) within a 1.3‐fold boundary, as indicated by the grey dashed lines at ± 0.38.
Phosphorylation changes of the conserved phosphosites, S235 and S236, on Rps601(C) and Rps602 (D–F), over 85 min of Torin1 (5 µM) treatment wild type (green) and Torin1‐resistant (brown) cells. M‐values (in brackets) represent the different multiplicities of the same phosphosites. Lines were fitted with the curve‐fitting function on Prism9 using the non‐linear regressions exponential one‐phase decay (C, D) or plateau followed by one‐phase decay (E, F) functions, respectively. Grey dashed lines indicate 2‐fold threshold.
Figure EV1Illustrated example for data visualisation tool
Example interface of the data visualisation tool for visualising the phosphorylation data of the 908 phosphosites (Table EV3) from the two phosphoproteomics time courses. Information regarding file upload, data filtering and subsequent visualisation as detailed in Materials and Methods.
Initial interface of the first “85‐min study” tab upon opening the application from the given link.
Demonstration of initial filtering of protein list based on conservation and subsequent display of graph with all phosphosites in top panel.
Illustration of individual phosphosite and specification of strain dataset to display in lower facet panels.
Interface of the second “40‐min study tab” interface with additional filtering criteria on sidebar panel and demonstration of the “Wrap” and “Download” functions.
17 major GO Biological Process categories for the 160 conserved proteins with phosphosites showing more than 2‐fold change within 40 min of Torin1 addition.
| GO term | Frequency | Gene names (Essential genes in bold) |
|---|---|---|
| Signalling (GO:0023052) | 37 ( | |
| Vesicle‐Mediated Transport (GO:0016192) | 33 ( | |
| Cytoplasmic Translation (GO:0002181) | 15 ( | |
| Ribosome Biogenesis (GO:0042254) | 15 ( | |
| Actin Cytoskeleton Organization (GO:0030036) | 13 ( | |
| Autophagy (GO:0006914) | 13 ( | |
| Establishment or Maintenance of Cell Polarity (GO:0007163) | 13 ( | |
| Chromatin Organization (GO:0006325) | 12 ( | |
| Membrane Organization (GO:0061024) | 12 ( | |
| Protein‐Containing Complex Assembly (GO:0065003) | 12 ( | |
| Transcription, DNA‐Templated (GO:0006351) | 12 ( | |
| Nucleocytoplasmic Transport (GO:0006913) | 11 ( | |
| mRNA Metabolic Process (GO:0016071) | 9 ( | |
| DNA Repair (GO:0006281) | 8 ( | |
| Mitotic Cell Cycle Phase Transition (GO:0044772) | 8 (0) | |
| Mitotic Cytokinesis (GO:0000281) | 8 ( | |
| Transmembrane Transport (GO:0055085) | 8 ( | |
| Uncategorised | 17 (0) |
Figure EV2Relative protein expression levels in wild type and tor1∆ after 40 min of Torin1 treatment
Scatter plot of the relative expression levels of individual protein in wild type and tor1∆ cells from the 40‐min proteomic time course experiment. Twofold thresholds are represented by grey dashed lines for either direction in the respective strains. Orange shaded areas indicate the expected regions with more than 2‐fold changes in relative protein expression levels in both wild type and tor1∆ cells, of which none were detected in the study. Points highlighted in red indicate the 23 proteins showing over 1.5‐fold difference in expression levels between wild type and tor1∆ before Torin1 treatment. But the relative expression levels of these proteins remain within a 2‐fold range upon inhibition of TOR activity inhibition.
Figure 3Identifying a core TORC1‐dependent protein interaction network in regulating rates of protein synthesis
Identification of a TORC1‐dependent protein interaction network through comparative phosphoproteomic studies.
Summary profile plots illustrating the minimum and maximum range of phosphorylation for the respective phosphorylation sites in wild type (in green) and tor1∆ (in yellow) cells, with lines indicating the median values of the phosphorylation profiles and the shaded areas representing the range of values. Values are normalised to their respective values at T = 0 min in each strain. Top two panels represent the 43 TORC2‐dependent phosphosites showing more than 2‐fold change in wild type (A) but within 1.3‐fold difference in tor1∆ cells (B). Bottom two panels illustrate the 158 phosphosites showing relative phosphorylation changes of more than 2‐fold in both wild type (C) and tor1∆ (D) cells.
Interaction network generated from the interactome analysis of the 49 potential TORC1‐dependent proteins conserved among fission yeast, budding yeast and human, based on collated annotations from the STRING database. Interactions between proteins were scored based on both functional and physical interactions from experimental, text mining and database sources only. Connections were drawn upon reaching a minimum interaction score of 0.4, and the lines were weighted to indicate the relative strength of the annotated interactions. The resultant network of the 28 connected proteins were functionally categorised based on their GO biological processes as annotated on PomBase and represented by the following colours, respectively: cytoplasmic translation (GO:0002181) and ribosome biogenesis (GO:0042254) in green, mRNA metabolism (GO:0016071) and transcription (GO:0006351) in purple, vesicle‐mediated transport (GO:0016192) in yellow and actin cytoskeleton organisation (GO:0030036) in brown. Grey nodes indicate proteins that were not assigned to the highlighted functional categories. Proteins that were identified as common in both phosphoproteomics studies are denoted by the darker hues of the respective colour categories, and the nodes of essential proteins are outlined in white (9/28).
All GO biological process categories for the 28 conserved interacting proteins.
| GO term | Frequency | Gene names |
|---|---|---|
| mRNA Metabolic Process (GO:0016071) | 8 | |
| Cytoplasmic Translation (GO:0002181) | 6 | |
| Vesicle‐Mediated Transport (GO:0016192) | 6 | |
| Actin Cytoskeleton Organization (GO:0030036) | 5 | |
| Establishment/ Maintenance of Cell Polarity (GO:0007163) | 4 | |
| Membrane Organization (GO:0061024) | 4 | |
| Mitotic Cytokinesis (GO:0000281) | 4 | |
| Protein‐Containing Complex Assembly (GO:0065003) | 4 | |
| Signaling (GO:0023052) | 3 | |
| Mitotic Cell Cycle Phase Transition (GO:0044772) | 2 | |
| Ribosome Biogenesis (GO:0042254) | 2 | |
| Transcription, DNA‐Templated (GO:0006351) | 2 | |
| Cell wall organization or biogenesis (GO:0071554) | 1 |
|
Figure 4The effects of TOR inhibition on S6K phosphorylation and rates of protein synthesis
Kinetic analyses on the identified phosphosites for the S6 kinase homologues in fission yeast, and the changes in rates of protein synthesis in the S6 kinase deletion mutant relative to wild type cells upon TOR inhibition.
Relative protein expression levels of the 3 S6 kinase homologues, Psk1, Sck1 and Sck2, plotted against time of Torin1 addition. Respective proteins are represented by the different coloured lines as detailed in the legend.
Relative phosphorylation level of the T632 phosphosite identified on Sck1 in the 40‐min time course study. Phosphorylation levels of both wild type (green) and tor1∆ (yellow) are presented relative to the value for wild type cells at T = 0 min. Grey dashed line indicates 2‐fold threshold.
Relative phosphorylation of the T16 phosphosite identified on Sck2 in the 85‐min time course study (background adjusted detailed in Materials and Methods). Grey dashed line indicates 2‐fold threshold.
Changes in the rates of protein synthesis upon Torin1 treatment (5 µM) measured for wild type and the S6 kinase deletion mutant (S6K 3x∆) plotted over time. Non‐linear regression exponential decay lines were fitted using the curve‐fitting function on Prism9. Error bars represent the standard deviation (SD) of data aggregated from 3 independent experiments.
Figure 5Examining potential essential translation‐related targets and the functional importance of phosphorylation on rates of protein synthesis upon TOR kinase inhibition
Phosphorylation kinetics of common phosphosites identified for 3 essential translation‐related proteins, and the effects of the tif471_18A phosphosite mutant on rates of protein synthesis upon Torin1 treatment.
Phosphosites identified on (A) Tif212 and (B) Erf1, respectively, showing 2‐fold phosphorylation change within 20 min of Torin1 (5 µM) addition. Both wild type (green) and tor1∆ (yellow) phosphorylation values are relative to the starting phosphorylation levels before Torin1 addition in wild type cells (T = 0 min). Grey dashed lines indicate 2‐fold threshold.
Relative phosphorylation levels of the 10 common phosphosites of Tif471 plotted against time after Torin1 treatment. Phosphorylation profiles are grouped based on phosphorylation kinetics, where 6 sites showed more than 1.5‐fold increase by 10 min (C), and the remaining 4 exceeded 2‐fold by 30 min (D). Grey dashed lines indicate 2‐fold threshold.
Changes in rates of protein synthesis of the tif471_18A mutant compared to the wild type control (tif471 +) upon Torin1 (5 µM) treatment. Residual rates of protein synthesis after 60 min of Torin1 treatment was 17% for the tif471_18A phosphomutant and 4.6% for the tif471 + control relative to starting levels in the respective strains. The two graphs represent the untransformed (E) and log2 transformed (F) rates respectively. Error bars represent the standard deviation (SD) of data aggregated from three independent experiments.
Figure EV3Relative growth rates in tif471_18A mutant is comparable to wild type cells
Representative plot of the relative growth rates as measured by the change in optical density (OD595) over time for tif471_18A mutant and control (tif471 +) cells. Values are background subtracted and gradients of the regression lines were 0.0011 for both strains, fitted using simple linear regression on Prism 9.
| Reagent/Resource | Reference or source | Identifier or catalog number |
|---|---|---|
|
| ||
| Nurse Lab | PN1 (TM11) | |
| Petersen Lab (Atkin | JP1669 (TM134) | |
|
| This study | TM97 |
| This study | TM74 | |
|
| This study | TM21 |
| This study | TM121 | |
|
| This study | TM156 |
|
| ||
| Plasmid: pSC‐A‐Amp‐tif471(wt)‐v5‐HphMX6 | This study | TMp16 |
| Plasmid: pSC‐A‐Amp‐tif471_13A‐v5‐HphMX6 | This study | TMp20 |
| Plasmid: pSC‐A‐Amp‐tif471_18A‐v5‐HphMX6 | This study | TMp21 |
|
| ||
| PCR primer: ATTCCTGAAGGATCTGATGGAAGC | This study | pTM101 |
| PCR primer: CATTAGACTTAAAGGAGCCGCA | This study | pTM102 |
| PCR primer: TTTGGAAAATTTTAATTTCATTC | This study | pTM111 |
| PCR primer: TTTACCCTCTTCCTCAGC | This study | pTM112 |
| PCR primer: acggaaagctgaggaagagggtaaaCGGGAAGCTGATAAAAAC | This study | pTM113 |
| PCR primer: atgaatgaaattaaaattttccaaaGCATTTCTCAATTACAATGTAG | This study | pTM114 |
| PCR primer: gaatcgatcgaggtttcgccgcttctggtgctggat | This study | pTM141 |
| PCR primer: atccagcaccagaagcggcgaaacctcgatcgattc | This study | pTM142 |
| PCR primer: ctggttttggtggtcctgcagagagaaagggcatt | This study | pTM143 |
| PCR primer: aatgccctttctctctgcaggaccaccaaaaccag | This study | pTM144 |
| PCR primer: ctctcgatccggcgcaaatgctcacgcccatgctggccct | This study | pTM145 |
| PCR primer: gggccagcatgggcgtgagcatttgcgccggatcgagag | This study | pTM146 |
| PCR primer: ACCGACTTTTCTGCTTTGGT | This study | spTM64 |
| PCR primer: AGCAATCCACCATTTAGCTCT | This study | spTM67 |
| PCR primer: TCCGTGATGACTTACACCGC | This study | spTM72 |
| PCR primer: TGAGTTAGAATCTTTTTGACCCCC | This study | spTM75 |
|
| ||
| Complete mini Protease Inhibitor Cocktail | Sigma Aldrich | Cat # 11836153001 |
| PhosSTOP phosphatase Inhibitor tablets | Sigma Aldrich | Cat # PHOSS‐RO |
| Propidium iodide solution | Biotium | Cat # 40017 |
| Torin1 | Torcris | Cat # 4247 |
| Pierce Trypsin Protease, MS Grade | ThermoFisher | Cat # 90058 |
|
| ||
| FlowJo v10.3.0 | FlowJo |
|
| Prism v9.0.0 | GraphPad |
|
| Rstudio v1.3 | Rstudio |
|
| Perseus v1.4.0.2.3 | Perseus |
|
| MaxQuant v1.5.0.13 | MaxQuant |
|
|
| ||
| PomBase | PomBase |
|
| PANTHER (GO Enrichment) | Gene Ontology |
|
| Clustal Omega | EMBL‐EBI |
|
|
| ||
| Mass spectrometry files | This study | |
| Data Visualisation Tool | This study |
|
|
| ||
| Ultrospec 2100 pro UV/visible spectrophotometer | Amersham Biosciences | Cat # 80‐2112‐21 (BioChrom) |
| Click‐iT® HPG Alexa Fluor® Protein Synthesis Assay Kits | ThermoFisher | Cat # C10428 |
| Dynabeads Protein A | ThermoFisher | Cat # 10002D |
| Dynabeads M‐270 Epoxy | ThermoFisher | Cat # 14302D |
| TMT 10plex Isobaric Label Reagent Set 1 × 0.8 mg | ThermoFisher | Cat # 90110 |
| High‐Select™ TiO2 Phosphopeptide Enrichment Kit | ThermoFisher | Cat # A32993 |
| High‐Select™ Fe‐NTA Phosphopeptide Enrichment Kit | ThermoFisher | Cat # A32992 |
| Pierce™ High pH Reversed‐Phase Peptide Fractionation Kit | ThermoFisher | Cat # 84868 |
| EASY‐Spray C18 column, 75 mm × 50 cm | ThermoFisher | Cat # ES803 |
| Orbitrap Fusion Lumos Tribrid Mass Spectrometer | ThermoFisher | Cat # IQLAAEGAAPFADBMBCX |
| BD LSRFortessa | BD Biosciences | Cat # 649225 |
| UltiMate 3000 HPLC System | ThermoFisher | Cat # 5041.0010 |
| QuikChange Multi Site‐Directed Mutagenesis | Agilent | Cat # 200514 |